• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Catalent Inc (NY: CTLT )

    55.80 -0.01 (-0.02%)
    Official Closing Price Updated: 7:00 PM EDT, May 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,334,425
    Open 55.80
    Bid (Size) 55.61 (1)
    Ask (Size) 56.41 (1)
    Prev. Close 55.81
    Today's Range 55.55 - 55.91
    52wk Range 31.80 - 60.20
    Shares Outstanding 170,341,553
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
    CTLT stock results show that Catalent missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
    Via InvestorPlace
    Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
    From Catalent, Inc.
    Via Business Wire

    Performance

    YTD
    +23.86%
    +23.86%
    1 Month
    -0.50%
    -0.50%
    3 Month
    -2.09%
    -2.09%
    6 Month
    +68.58%
    +68.58%
    1 Year
    +28.01%
    +28.01%

    More News

    Read More
    Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
    Via Benzinga
    Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
    From Robbins LLP
    Via Business Wire
    Beyond The Numbers: 6 Analysts Discuss Catalent Stock
    Via Benzinga
    (CTLT) - Analyzing Catalent's Short Interest
    Via Benzinga
    In-Depth Examination Of 5 Analyst Recommendations For Catalent
    Via Benzinga
    Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
    Via Benzinga
    Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
    From Robbins LLP
    Via GlobeNewswire
    Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
    Via The Motley Fool
    Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
    Via Talk Markets
    Did Novo Nordisk Just Get a Jump on Eli Lilly?
    Via The Motley Fool
    Exposures Product Safety
    The Top 3 Pharma Stocks to Buy in March2024
    Via InvestorPlace
    Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
    Via Benzinga
    Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
    From Catalent, Inc.
    Via Business Wire
    Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
    Via Benzinga
    Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
    Via The Motley Fool
    Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
    Via Benzinga
    Topics ETFs Stocks
    Exposures US Equities
    Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
    Via Benzinga
    Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
    Via Benzinga
    CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    S&P 500's surge to new highs: Bull trap hiding in plain sight?
    Via MarketBeat
    Topics ETFs Economy Stocks
    Exposures Interest Rates US Equities
    Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
    Via Benzinga
    Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.